The effect of metformin on body mass index and metabolic parameters in non-diabetic HIV-positive patients: a meta-analysis

We sought to evaluate the effetc of metformin on body mass index (BMI) and metabolic parameters in HIV-positive patients. We performed a comprehensive search through five major indexing databases, using keywords (“metformin” OR “dimethylguanylguanidine” OR “biguanide” OR “Glucophage”) AND (“HIV” OR “human immunodeficiency virus” OR “AIDS” OR “Acquired immunodeficiency syndrome”), and all possible combinations until January 15, 2021. We measured standardized mean differences (SMD) and 95% confidence intervals (CI) for each outcome. We finally included 12 RCTs (577 participants, 274 in the metformin group and 303 in the comparators). Metformin did not significantly change BMI index compared to various comparators. Metformin generally improve LDL levels (SMD = 0.29, 95% CI: − 1.00 1.57, P = 0.01), HDL levels (SMD = − 0.15, 95% CI: − 0.72 0.41, P = 0.001), triglycerides values (SMD = 0.46, 95% CI: − 0.36 1.27, P < 0.00001), fasting glucose (SMD = − 0.82, 95% CI: − 1.80 0.15, P < 0.00001), insulin 120 min (SMD = − 0.82, 95% CI: − 1.59–0.04, P = 0.02), and glucose 120 min (SMD = − 1.24, 95% CI: − 2.57 0.10, P < 0.0001), but worsened total cholesterol values (SMD = 1.24, 95% CI: − 0.98 3.46, P = 0.0001). Metformin is safe for weight loss in obese people; however, this drug may not be suitable for everyone, especially those who are not overweight. Nevertheless the body of evidences may suggest that metformin had promising impacts on metabolic parameters in patients with both HIV, it is still unknown that such surrogate changes will translate to long-standing clinical advantages.